Full Press Release Details
Zynex Receives FDA Clearance for its
Blood Volume Monitor
CO - February 25, 2020 - Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing
in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and
neurological diagnostics, today announced the U.S. Food and Drug Administration ("FDA") granted
510(k) clearance for sale in the U.S. for the CM-1500 Blood Volume Monitor.
Thomas Sandgaard, CEO said: "I
am very excited to finally have obtained FDA clearance to sell our non-invasive Blood Volume Monitor in the U.S. The device is
fully developed, has performed well in multiple clinical trials and can guide medical professionals in hospitals and surgical
centers towards better fluid management during surgery and in recovery settings. Fluid management during and after surgery is
one of the largest un-met needs in hospitals today."
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices
used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke
and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers.
For additional information, please visit: www.zynex.com.
Safe Harbor Statement
This release contains forward-looking
statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such
forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development
and/or otherwise are not statements of historical fact.
In some cases, you can identify
forward-looking statements by terminology, such as "expects," "anticipates," "intends," "estimates,"
"plans," "believes," "seeks," "may," "should," "could,"
"will," "future," "projects," "strategy," or the negative of such terms or other
similar expressions.
Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and
other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties,
risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results
and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not
rely on any of these forward-looking statements. Important factors that could cause actual results to materially differ from forward-looking
statements include, but are not limited to, the need to obtain FDA clearance and CE marking of new products, the acceptance of
new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need
to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies,
our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales
strategy including a strong direct sales force and other risks described in our filings with the Securities and Exchange Commission
including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2018.
Any forward-looking statement made
by us in this release is based only on information currently available to us and speaks only as of the date on which it is made.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.
Amato And Partners, LLC
Investor Relations Counsel